68 ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS

Methods: Thirty-five patients (n = 35) naive CHC-G1 were recruited. Group A (n =18): p-IFNa 135mcg once weekly, Telaprevir 750mg two tablets-TID four days and three tablets BID post dialysis for three days; along with RBV 400mg daily for 12 weeks followed by p-IFNa 135mcg plus RVB 400mg till 24 weeks. Group B (n =17) p-IFNa 135 mcg once weekly with Telaprevir same as Group A with RBV 200mg for 12 weeks followed by p-IFNa 135mcg with RBV 400mg till 48 weeks. Viral load to follow RGT. Results: See the table. Conclusion: This study demonstrates higher SVR comparing traditional SOC on hemodialysis CHC-G1 patients. Extended 48 weeks had no benefits. Multi-center trials to follow.